DRS
BMRN icon

Deane Retirement Strategies’s BioMarin Pharmaceuticals BMRN Stock Holding History

Deane Retirement Strategies’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-20,382
Closed -$1.85M – 62
2017
Q2 		$1.85M Sell
20,382
-87
-0.4% -$7.92K 1.48% 11
2017
Q1 		$1.8M Buy
+20,469
New +$1.82M 1.49% 22

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deane Retirement Strategies's BMRN Position: Q3 2017 in Review

Deane Retirement Strategies sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2017, closing a stake of 20,382 shares — an estimated $1.85M sold.

Deane Retirement Strategies first reported a position in BMRN in Q1 2017 and held it in 2 quarters. The position peaked at $1.85M in Q2 2017. 411 funds tracked by Wall St. Rank hold BMRN as of Q3 2017.

  • Deane Retirement Strategies reported no remaining BioMarin Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Deane Retirement Strategies sold 20,382 BioMarin Pharmaceuticals shares in Q3 2017, an estimated $1.85M.
  • Deane Retirement Strategies first reported a position in BioMarin Pharmaceuticals in Q1 2017 and held it in 2 quarters.
  • Deane Retirement Strategies's BioMarin Pharmaceuticals position peaked at $1.85M in Q2 2017.
  • 411 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2017.

Based on Deane Retirement Strategies's 13F filing for Q3 2017, filed 19 Oct 2017.